Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $102.00 Average PT from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have received a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $102.5833.

MIRM has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. TD Cowen restated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Finally, Stifel Nicolaus upped their price objective on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th.

Insider Transactions at Mirum Pharmaceuticals

In related news, insider Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $90.27, for a total transaction of $623,855.97. Following the completion of the sale, the insider owned 11,305 shares in the company, valued at approximately $1,020,502.35. This trade represents a 37.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 14.36% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Jump Financial LLC lifted its holdings in shares of Mirum Pharmaceuticals by 839.7% during the 2nd quarter. Jump Financial LLC now owns 148,689 shares of the company’s stock worth $7,567,000 after acquiring an additional 132,866 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in Mirum Pharmaceuticals during the third quarter valued at approximately $1,728,000. Eventide Asset Management LLC lifted its stake in Mirum Pharmaceuticals by 4.4% during the second quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock worth $134,224,000 after purchasing an additional 110,485 shares during the last quarter. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter valued at $11,071,000. Finally, Strs Ohio bought a new position in shares of Mirum Pharmaceuticals in the 1st quarter valued at $550,000.

Mirum Pharmaceuticals Price Performance

MIRM opened at $93.27 on Monday. The stock’s 50-day moving average price is $76.34 and its 200 day moving average price is $70.16. Mirum Pharmaceuticals has a 12-month low of $36.88 and a 12-month high of $93.99. The firm has a market cap of $4.79 billion, a price-to-earnings ratio of -108.45 and a beta of 0.48. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.Mirum Pharmaceuticals’s revenue for the quarter was up 47.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.30) EPS. As a group, sell-side analysts expect that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.